Back to search

University of Thessaly (UTH)

Επιπολασμός αντισωμάτων κατά μικροσωμίων ήπατος νεφρών (αντί - LKM) και άλλων μη - οργανοειδών αυτοαντισωμάτων σε ασθενείς με χρόνια ηπατίτιδα C

Abstract

dc:description

Hepatitis C virus (HCV) is an hepatotropic and lymphotropic virus, who provokes a chronic, ‘silent’ and non symptomatic disease, in the majority of patients, being a major problem of public health, worldwide. In addition, HCV is characterized by the induction of autoimmune reactions, as can be demonstrated by the presence of extrahepatic manifestations and organ specific and non-organ specific autoantibodies. A lot of these autoantibodies are similar with those that characterize the autoimmune liver diseases. The extrahepatic manifestations and autoantibody production can be promoted by the administration of antiviral treatment (a-interferon, a-IFN).The aims of the study were: To evaluate the prevalence of liver-kidney microsomal antibodies (anti-LKM) and of several other autoantibodies [antinuclear (ANA), antimitochondrial (AMA), smooth muscle autoantibodies (SMA), antineutrophil cytoplasmic antibodies (ANCA), parietal cells antibodies(PCA), anticardiolipin antibodies (anti-CL), autoantibodies against liver cytosol 1 antigen (anti-LC1), antibodies against double stranded DNA (anti-dsDNA)] in a large non selected sample of Greek HCV positive patients (n=303), independently of being under treatment or not, since there is no such information for our country. To evaluate the parameters, that are possibly correlated with the presence of the autoantibodies mentioned above and if these autoantibodies are of any clinical significance or not. For these reasons, the presence of the autoantibodies was associated with certain demographic, epidemiologic, clinical, laboratory, histologic and virologic characteristics of HCV positive patients, as well as with the administration of antiviral treatment. To investigate the target autoantigens of anti-LKM antibodies in a non-selected part of the patients (n=39), with the use of molecular methods.It was found, that the prevalence of the autoantibodies studied, in Greek HCV positive patients was very high (90% presence of autoantibodies of at least one specificity). More precisely, the detection of anti-LKM antibodies in Greek HCV positive patients was not rare at all, since they were found in 4.6% of them. However, in the group of non-selected patients who were tested, the target autoantigen of anti-LKM antibodies was proved to be, in the majority of cases, other than cytochrome P4502D6 (CYP 2D6). In addition, for the first time, anti-CYP 2D6 and antibodies against UDP glucuronyl transferase (anti-UGT) were detected silmutaneously, in a HCV positive/HDV negative patient. The more frequently detected autoantibodies were SMA (71.6%) and ANA (63%). However, their specificity was different than that of the respective autoantibodies detected in autoimmune hepatitis 1 (AH-1). In addition, it was confirmed that ANCA and anti-LC1 antibodies are not exclusively detected in AH-1 and autoimmune hepatitis 2 (AH-2) respectively, since they were found in 52.8% and 3% of patients suffering from chronic hepatitis C, respectively. Futhermore, AMA (7.6%), PCA (5.4%), anti-CL (20.4%) and anti-dsDNA (26.1%) antibodies, were also detected. The majority of the autoantibodies tested were not associated with demographic, epidemiologic, histologic, virologic data or the presence of extrahepatic manifestations. However, some of them (for example ANA, SMA, ANCA or the presence of one autoantibody at least) were associated with advanced disease (cirrhosis) and biochemical activity (elevated values of aminotransferases), which points them out as additional laboratory markers of progressive disease. Nevertheless, their pathogenetic role in progression of liver disease is uncertain. Their presence seems rather to be the result of a chronic B lymphocytic activation caused by HCV or neo-antigen formation in the context of hepatocellular destruction. Among the epidemiologic and demographic parameters studied, statistically significant association was found between a) age and anti-CL antibody positivity (p<0.05) b) iv drug abuse and anti-dsDNA antibody positivity (p=0.011) and c) alcohol abuse and anti-CL antibody positivity (p<0.05).None of the HCV positive/anti-CL positive patients presented or developed during the follow up period manifestations suggestive of antiphospholipid syndrome (APLS) (thrombosis, recurrent fetal losses, thrombocytopenia). The above findings were confirmed by the fact that, in a non selected sample of HCV positive patients (n=174) of the study, anti-CL antibodies were found to be independed from the ‘co-factor’ beta 2-glucoprotein I (β2-GPI) and therefore, ‘non-pathogenic’, while, ‘non-pathogenic’ anti-CL antibodies were found in a high percentage (14%) of the patients with chronic hepatitis B, who were studied (disease control group). However, prospective studies with long term follow up (>10 years) of HCV positive/anti-CL positive patients are needed, in order to determine the clinical significance of anti-CL antibodies in chronic viral infections.In addition, there was found no correlation between the viral load and any of the autoantibodies, while the presence of genotype 1b was associated only with the presence of PCA (p=0.017). PCA was also, the only autoantibody marker associated with the administration of antiviral treatment (p=0.029). The above findings suggest the need of prospective studies in order to investigate the possible induction of these autoantibodies by the antiviral treatment and their role in the response to such a treatment. Conclusively, the present study showed that the detection of autoantibodies is very frequent in Greek patients with chronic HCV infection, but their presence is rather a result of a chronic B lymphocytic activation from this lymphotropic virus, possibly in combination with the genetic predisposition of the host or neo-antigen formation in the context of hepatocellular destruction. From the clinical point of view, it seems that some non-organ specific autoantibodies detected during chronic HCV infection (for example ANA, SMA, ANCA) can be used as additional laboratory markers of progression liver disease. Long-lasting, prospective studies are needed in order to determine the clinical significance and the precise role of those autoantibodies, as well as that of anti-CL and PCA, in chronic hepatitis C.

Degree

thesis:*
Grantor dc:publisher
University of Thessaly (UTH)
Year dc:date
2003

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Zachou, Kalliopi
  • Ζάχου, Καλλιόπη

Subjects

dc:subject × 20

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/35300

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Zachou, Kalliopi; Ζάχου, Καλλιόπη. Επιπολασμός αντισωμάτων κατά μικροσωμίων ήπατος νεφρών (αντί - LKM) και άλλων μη - οργανοειδών αυτοαντισωμάτων σε ασθενείς με χρόνια ηπατίτιδα C. University of Thessaly (UTH), 2003. http://hdl.handle.net/10442/hedi/35300